Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients - Imunon (

Imunon reports early Phase 2 data showing lower residual disease and higher ctDNA clearance with IMNN-001 in ovarian cancer.

Raccontata dabenzinga.com